| 代码 | 名称 | | 涨幅% ↓ | 总市值 | 年初至今涨幅% | | --- | --- | --- | --- | --- | --- | | 300436 | 广生堂 | 1 | 20.00 | 153亿 | 8.00 | | 301093 | 中三股份 | 资 | 12.00 | 138亿 | 63.89 | | 600774 | 汉商集团 * | | 10.00 | 34.08亿 | 26.37 | | 300683 | 海特生物 | 资 | 7.92 | 43.71亿 | 20.41 | | 688759 | 必贝特-U | 1 | 6.64 | 249亿 | 90.09 | | 300204 | 舒泰神 | 1 | 5.78 | 136亿 | 4.58 | | 688222 | 成都先导 | 中 | 5.42 | 138亿 | 46.78 | | 000078 | 海王生物 | 1 | 5.23 | 101亿 | 10.40 | | 600998 | 九州通 | 1 | 4.71 | 280亿 | 8.59 | | 301230 | 泓博医药 | | 4.60 | 67.60亿 | 62 ...

Investment Rating - The industry investment rating is "Strong Buy" and is maintained [2]. Core Insights - The investment value of the AI + pharmaceutical industry lies in the analysis of the current state and future judgment of the industry. Understanding the role of AI in pharmaceuticals, its business models, growth potential, key growth factors, and competitive barriers is essential [4]. - AI in pharmaceuticals primarily enhances efficiency and innovation. The most mature applications of AI in drug development focus on cost reduction and efficiency improvements in preclinical stages, significantly shortening development cycles and reducing costs [5]. - The global market for AI-enabled drug development is projected to grow from $11.9 billion in 2023 to $74.6 billion by 2032, with a CAGR of 22.6% [5]. - The industry has seen a significant increase in investment, with the AI + CRO/AI + Biotech model being a major trend for profitability. High-quality data production capabilities are identified as a core competitive advantage [5][6]. Summary by Sections AI's Role in Pharmaceuticals - AI in drug development combines technologies like NLP and deep neural networks to enhance efficiency and expand innovation space. It integrates vast biomedical data to empower the entire drug development process [9]. - AI's application is most effective in the preclinical research phase, where it can reduce costs by over 90% and significantly shorten development timelines [21]. Market Size and Commercialization Focus - The AI + pharmaceutical financing landscape has seen rapid growth since 2015, with a total of $24.6 billion raised by 2022. However, there has been a decline in financing activity due to global economic conditions [48]. - The commercial focus is on molecular entities, with the industry not yet forming a unified paradigm, leading to structural differentiation among companies [52][68]. Business Models - The industry features three main business models: SaaS, AI + CRO, and AI + Biotech. The AI + CRO model is predominant, leveraging AI technology to provide outsourced drug development services [62][63]. - SaaS models face challenges due to limited market size and high competition, making them less favorable for new entrants [67]. Key Players and Competitive Landscape - The report highlights leading companies in the AI pharmaceutical space, including Insilico Medicine, Relay Therapeutics, and Schrodinger, which are involved in various stages of drug development [53][54]. - The competitive landscape is characterized by a "Matthew Effect," where leading players dominate due to their established capabilities and resources [6].

Investment Rating - The industry investment rating is "Strong Buy" [2]. Core Insights - The investment value of the AI+pharmaceutical industry lies in analyzing the current status and future potential of AI's role in drug development, focusing on efficiency and innovation [4]. - AI enhances drug development by reducing costs and increasing efficiency, particularly in the preclinical phase, where AI virtual screening significantly lowers the number of compounds needed for real trials, thus shortening development cycles and costs [5]. - The global market for AI-enabled drug development is projected to grow from $11.9 billion in 2023 to $74.6 billion by 2032, with a CAGR of 22.6% [5]. - The industry is experiencing a structural differentiation trend in financing, with a total of $24.6 billion raised globally for AI+drug development since 2015, although there has been a decline in financing activity in 2022 due to economic downturns [48]. Summary by Sections AI's Role in Pharmaceuticals - AI in drug development combines technologies like NLP and deep learning to enhance efficiency and expand innovation space across the entire drug development process [9]. - AI's most mature applications are in preclinical research, where it can reduce costs by over 90% and significantly shorten development timelines [22]. High-Quality Data Production as Core Competitiveness - The ability to produce high-quality data is identified as a core competitive advantage in the industry, as it enables effective algorithm iteration and data accumulation [6]. - The industry faces challenges with "data silos," where high-quality data is scarce and not shared, making data production capabilities crucial for long-term competitiveness [6]. Market Size and Commercialization Focus - The AI+pharmaceutical financing landscape has seen rapid growth, with significant investments concentrated in the US and China, although the latter's share has decreased recently [48]. - The commercial focus is shifting towards molecular entities, with AI+CRO and AI+Biotech models emerging as dominant trends for revenue generation [58]. Business Models - The industry features three main business models: SaaS, AI+CRO, and AI+Biotech, with the latter two being more prevalent due to their higher revenue potential and lower risk exposure [63][67]. - SaaS models face challenges due to limited market size and high competition, suggesting that they may not be suitable for new entrants in the industry [67].

证券之星消息，1月21日医疗服务板块较上一交易日上涨0.18%，南模生物领涨。当日上证指数报收于 4116.94，上涨0.08%。深证成指报收于14255.12，上涨0.7%。医疗服务板块个股涨跌见下表： 从资金流向上来看，当日医疗服务板块主力资金净流入5050.97万元，游资资金净流入3.24亿元，散户资 金净流出3.75亿元。医疗服务板块个股资金流向见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688265 | 南模生物 | 49.79 | 7.01% | 2.00万 | i 9802.06万 | | 300683 | 海特生物 | 29.67 | 5.74% | 10.78万 | 3.22 Z | | 300244 | 迪安诊断 | 26.46 | 5.59% | 79.63万 | 21.30亿 | | 600568 | ST中珠 | 2.64 | 5.18% | 37.65万 | 9806.43万 | | 600763 | 通策医疗 | 46.51 | 4.99% | 19. ...

转自：前瞻产业研究院 以下数据及分析来自于前瞻产业研究院医药研发外包(CRO)研究小组发布的《中国医药研发外包（CRO）行 业市场前瞻与投资战略规划分析报告》。 行业主要上市公司：目前国内CRO行业主要的上市公司有药明康德(603259.SH)、康龙化成(300759.SZ)、泰 格医药(300347.SZ)、凯莱英(002821.SZ)、昭衍新药(603127.SH)、九洲药业(603456.SH)、皓元医药 (688131.SH)、博腾股份(300363.SZ)、成都先导(688222.SH)、药石科技(300725.SZ)等。 本文核心数据：CRO产业市场规模 行业概况 2、CRO行业产业链剖析 中国 CRO 产业链贯穿药品全生命周期，可以分为三个阶段。研发阶段CRO，含临床前药物发现、化合物合 成等基础研发与临床阶段试验等;生产阶段CMO/CDMO，覆盖化学原料药、生物药、化学药制剂等不同类型 药物的生产环节;销售阶段CSO，以渠道管理为核心，配套推广营销与市场监测，服务企业、科研机构、医 1、CRO的定义 合同研究组织 (Contract Research Organization, CRO) 是指 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 002219 | 新里程 | 2.57 | 9.83% | 311.92万 | | 7.78亿 | | 000504 | *ST生物 | 8.93 | 5.06% | 3.98万 | 3501.24万 | | | 002524 | 光正眼科 | 4.42 | 2.31% | 13.72万 | 5988.13万 | | | 688238 | 和元生物 | 7.61 | 2.28% | 14.19万 | | 1.08亿 | | 688710 | 益诺思 | 64.22 | 1.68% | 1.52万 | 9656.70万 | | | 002172 | 澳洋健康 | 4.37 | 1.63% | 39.67万 | | 1.72亿 | | 300244 | 迪安诊断 | 25.62 | 1.39% | 74.35万 | | 19.64亿 | | 002622 | 皓宸医疗 | 3.11 | 1.30% | 20.40万 | 6319.80万 ...

Economic Information - Several smartphone manufacturers, including Xiaomi, OPPO, vivo, and Transsion, have lowered their annual shipment forecasts, with Xiaomi and OPPO reducing by over 20%, vivo by nearly 15%, and Transsion to below 70 million units [2] - Silver prices have surged over 50% in one month and over 150% in six months, impacting the photovoltaic industry, which consumes a significant amount of silver. The cost of raw materials for solar cells has increased by nearly 20% due to rising silver prices [2] - The company Xibei is expected to incur cumulative losses exceeding 600 million yuan from September 2025 to March 2026, leading to the closure of 102 stores, accounting for 30% of its total outlets [2] Company Alerts - Shenghong Technology anticipates a net profit increase of 260%-295% year-on-year for 2025, although Q4 performance fell short of expectations [4] - Cambridge Technology expects a net profit increase of 51%-67% year-on-year for 2025, with Q4 results also below expectations [4] - Multiple companies, including Weimait and Youyan Silicon, have announced plans to reduce their shareholdings by up to 4.98% and 3% respectively [4][11] Overseas Alerts - The three major U.S. stock indices collectively declined last Friday, with the Nasdaq China Golden Dragon Index dropping by 1.15%. Notable declines were seen in Chinese stocks such as Alibaba and JD.com [5] - The European Union is considering imposing tariffs on U.S. goods worth 93 billion euros in response to U.S. tariffs on eight European countries, which could take effect on February 6 if no agreement is reached [5]

Core Viewpoint - The announcement details a share reduction plan by Shenzhen Jun Tian Investment Enterprise (Limited Partnership), which holds 10,067,751 shares of Chengdu Xian Dao Pharmaceutical Development Co., Ltd., representing 2.51% of the company's total share capital [2][3][4]. Group 1: Shareholder Reduction Plan - Shenzhen Jun Tian plans to reduce its holdings of 10,067,751 shares through centralized bidding and block trading, with the reduction period set from January 22, 2026, to April 21, 2026 [4]. - The shareholder has obtained the necessary approvals and is compliant with relevant regulations regarding the reduction of shares held by venture capital fund shareholders [4][6]. - The reduction will be limited to a maximum of 1% of the total shares through centralized bidding and 2% through block trading within any consecutive 30-day period [4]. Group 2: Shareholder Background - As of the announcement date, Shenzhen Jun Tian holds 10,067,751 shares, which is 2.51% of the total share capital of Chengdu Xian Dao [3]. - The shareholder has made commitments regarding the reduction, including a maximum of 50% of their shares held prior to the public offering can be reduced within two years after the lock-up period [6]. Group 3: Compliance and Regulations - The reduction plan is in accordance with the relevant laws and regulations, including the Securities Law of the People's Republic of China and specific guidelines for venture capital fund shareholders [9]. - The company will adhere to all legal and regulatory requirements during the share reduction process and will fulfill its information disclosure obligations [9].

Shareholder Reductions - RS Technologies and Cangyuan Investment plan to reduce their holdings by no more than 3% in Youyan Silicon [1] - Yuexiu Capital intends to sell no more than 1% of the total share capital of CITIC Securities [1] - Multiple shareholders of Ruimaite plan to collectively reduce their holdings by no more than 4.98% [1] - The controlling shareholder of Brother Technology plans to reduce its holdings by no more than 2% [1] - Jinggangshan Chengxing intends to reduce its holdings in Guanggang Gas by no more than 0.9997% [1] - The controlling shareholder of Lianchuang Optoelectronics, Electronic Group, plans to reduce its holdings by no more than 2% [1] - Shenzhen Jun Tian, a shareholder of Chengdu Xian Dao, plans to reduce its holdings by no more than 2.51% [1] - Shareholder Fan Jun of Xidi Micro plans to reduce no more than 251,230 shares [1] - Shareholder Cheng Gao Century of Decai Co., Ltd. plans to reduce 4.1973 million shares [1] - Hangzhou Xintou and its concerted action party Hangzhou Haoyue have cumulatively reduced 1.29% of shares in Meinian Health [1] - Guotou Chuangye Fund has cumulatively reduced 1.06% of shares in Fuchuang Precision [1] - New Momentum Fund has cumulatively reduced 0.9926% of shares in Shannon Chip Creation [1] - Deputy General Manager Li Zuqing of Guangli Technology plans to reduce no more than 701,600 shares [1] Other Notable Events - Yuan Zhishuang of Dingxin Communications is under investigation by the Securities Regulatory Commission for suspected short-term trading of company shares [1] - Shimao Energy has terminated its plans for a change in control [1]

北京商报讯1月16日晚间，成都先导（688222）发布公告称，公司股东深圳市钧天投资企业（有限合 伙）（以下简称"深圳钧天"）拟通过集中竞价和大宗交易的方式减持其所持有的公司股份合计1006.78 万股，拟减持股份占公司总股本的比例约为2.51%。 公告显示，截至公告披露日，公司股东深圳钧天持有公司股份1006.78万股，占公司总股本的2.51%。这 也意味着，深圳钧天此次减持系清仓式减持。 （文章来源：北京商报） ...